Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report

Chie Kitahara1, Shuhei Morita1,*, Shohei Kishimoto1, Shohei Matsuno1, Shinsuke Uraki1, Ken Takeshima1, Yasushi Furukawa1, Hidefumi Inaba1, Hiroshi Iwakura1, Hiroyuki Aiyasu1, Hiroto Furuta1, Masahiro Nishi1, Takashi Akamizu1,2

1The First Department of Medicine, Wakayama Medical University, Wakayama, Japan, and 2Kuma Hospital, Kobe, Japan

Keywords
Empagliflozin, Intraoperative euglycemic ketoacidosis, Sodium–glucose cotransporter 2 inhibitor

*Correspondence
Shuhei Morita
Tel.: +81-73-441-0625
Fax: +81-73-445-9436
E-mail address: smorita@wakayama-med.ac.jp

J Diabetes Investig 2021; 12: 664–667
doi: 10.1111/jdi.13365

INTRODUCTION
Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are widely used in patients with diabetes mellitus. However, regulatory agencies issued a warning that SGLT2is could cause diabetic ketoacidosis (DKA)1. DKA associated with SGLT2is can even occur when glucose levels are lower than expected, known as euglycemic DKA (eDKA), and often occurs during the perioperative period1,2. Cases of eDKA associated with SGLT2is have been reported after surgery1,2, but there is no report of occurrence during the surgery. Here, we present a patient with type 2 diabetes and bacterial empyema, who underwent surgery without a sufficient period of empagliflozin withdrawal. He developed intraoperative eDKA, but rapidly recovered after its early identification and management.

CASE REPORT
A 59-year-old man had a 12-year history of type 2 diabetes mellitus initiated with 10 mg of empagliflozin 18 months earlier, and clinically titrated to 25 mg along with intensive insulin therapy. During the period of treatment with empagliflozin, uric ketone had not been detected at every visit. The patient presented with high fever and chest pain for 2 weeks, and was admitted to a neighboring hospital. He was diagnosed as having left bacterial empyema, and treated with antibiotics for 4 days; however, as his symptoms persisted, he was transferred to Wakayama Medical University (Wakayama, Japan) for surgical treatment. He had a fever of 37.2°C, and weak pulmonary sound on the left side. The patient’s bodyweight, height and body mass index were 69 kg, 169 cm and 24.1 kg/m², respectively. Laboratory data showed a severe infectious state (Table 1). Chest radiography and computed tomography images showed a large pleural effusion (Figure 1). On the day the patient was transferred to our hospital, he was treated with empagliflozin and insulin for diabetes at the former hospital (day 0; Figure 2). Empagliflozin was taken for the last time 28 h before surgery. He had no appetite loss nor digestive symptoms on that day. He was treated with insulin glargine 13 h before surgery.
After overnight fasting for 18 h, the patient underwent thoracoscopic debridement and intrathoracic lavage (day 1; Figure 2). His surgery was initiated with drip infusion of extracellular fluid with 1% glucose without insulin. Based on the information of having diabetes from the former hospital, his arterial blood gas was measured during surgery. Approximately 2 h after the initiation of surgery, he was found to be acidotic on arterial blood gas with 162 mg/dL of blood glucose level (Figure 2). A urine test for ketone showed a positive result. Laboratory tests showed elevated levels of total ketone bodies, acetoacetic acid and 3-hydroxybutyric acid in serum (Figure 2). Subsequently, the patient was started on an insulin infusion with drip infusion of 5% glucose immediately after the consultation from the anesthesiologist to the first department of medicine. He awoke from anesthesia normally and showed no digestive symptoms. After the continuous insulin infusion, his acidosis and ketosis gradually resolved over the next 24 h. Approximately 2 weeks later, his bacterial empyema had almost resolved. During these 2 weeks, he was treated with insulin alone for diabetes and did not present ketosis or acidosis.

Written informed consent was obtained from the patient.

**DISCUSSION**

SGLT2is are widely used as excellent agents for managing diabetes, while providing metabolic, cardiovascular and renal benefits. However, several adverse effects are concerned. DKA is a significant risk for patients taking SGLT2is, especially when there are precipitating factors, such as illness, infection and surgery. In several countries, it is recommended that SGLT2is be discontinued preoperatively. The half-life of 25 mg empagliflozin is reported to be 18.0 h according to the package insert. In the present case, empagliflozin was taken for the last time 28 h before surgery. However, in the case of surgery, it might be necessary to consider the potential effects of anesthesia and muscle relaxants on the half-life. In Australia, for example, cessation at least 3 days preoperatively is recommended based on the half-life and dose-dependent offset time of SGLT2is. In the present case, besides the use of SGLT2is with an insufficient withdrawal period, the patient was speculated to have infection with empyema and surgery as risk factors of DKA. In particular, as the present patient initially showed mixed acidemia, possibly as a result of the retention of carbon dioxide under the isolated one-lung ventilation in addition to accumulation of ketone, it is necessary to pay attention to the management of DKA during thoracic surgery.

![Figure 1](http://wileyonlinelibrary.com/journal/jdi)  
Figure 1 | Chest radiography (a) and computed tomography (b) before thoracoscopic debridement and intrathoracic lavage (day 0).
low concentration of glucose without insulin. Although insulin glargine was injected the night before, it is also possible that an insufficient dosage of glucose and insulin made the DKA worse in the present case.

Early detection and intervention are critical for management of DKA associated with SGLT2is. The US Food and Drug Administration highlighted awareness among practitioners, DKA symptoms and the potential for lower than expected blood glucose levels when precipitating factors for DKA associated with SGLT2is are present in patients. However, as symptoms are atypical and the blood glucose levels could be lower than expected, the diagnosis tends to be delayed in DKA associated with SGLT2is. In the present case, it is possible that eDKA had already developed before the surgery, although the patient had no symptoms of acidemia at that point. Thus, when it is difficult to take a sufficient withdrawal period of SGLT2is preoperatively, it is important to monitor ketone and acidosis, even before surgery, for the early detection and immediate management of DKA.

Several situations/diseases are raised as the general differential diagnosis of euglycemic ketoacidosis: pregnancy, restriction on caloric intake, glycogen storage diseases or defective gluconeogenesis as a result of alcohol abuse or chronic liver disease. As for the mechanism of eDKA associated with SGLT2is under stress, situations, such as delivery of a potentially low dose of insulin, increased secretion of counter hormones and dehydration status on the surgical day, could be speculated.

Under stress, such as surgery or illness, increased secretion of counter hormones, such as glucagon, leads to ketogenesis owing to such reasons as lipolysis providing sufficient free fatty acid substrate for production of ketone bodies or hepatic glucose production. Meanwhile, in patients treated with both SGLT2is and insulin, increased renal excretion of glucose might result in treatment with insufficient insulin to suppress lipolysis and ketogenesis, even if blood glucose levels are not increased. Therefore, sufficient insulin delivery, and careful clinical and biochemical monitoring are required to prevent perioperative eDKA in patients treated with dual SGLT2is and insulin.

In summary, we presented a patient with type 2 diabetes and bacterial empyema, who developed intraoperative eDKA associated with empagliflozin. This is the first case of eDKA associated with SGLT2is during thoracic surgery, which could be rapidly resolved by emergent intervention. When patients are taking SGLT2is, especially those with precipitating factors, it is clinically important to be aware of the potential risk of eDKA and to increase monitoring for the immediate initiation of treatment.

ACKNOWLEDGMENTS
We acknowledge proofreading and editing by Benjamin Phillis at the Clinical Study Support Center at Wakayama Medical University. This work was supported by SRF (TA).

---

Figure 2 | Patient’s clinical course. Black circles and blank circles represent blood glucose and C-reactive protein levels, respectively.
DISCLOSURE
The authors declare no conflict of interest.

REFERENCES
1. Fleming N, Hamblin PS, Story D, et al. Evolving evidence of diabetic ketoacidosis in patients taking sodium glucose cotransporter 2 inhibitors. J Clin Endocrinol Metab 2020; 105: dgaa200.
2. Thiruvenkatarajan V, Meyer EJ, Nanjappa N, et al. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth 2019; 123: 27–36.
3. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 2017; 13: 11–26.
4. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295–2306.
5. Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia 2017; 60: 1385–1389.
6. Perry RJ, Rabin-Court A, Song JD, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun 2019; 10: 548.
7. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015; 100: 2849–2852.